RxDoctor Payments Data

Claiborne Whitworth, MD

Urology · Lexington, VANPI 1073592796

Payments from drug & device makers

$621in general payments, 2019–2025

Across 32 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$158
  • Johnson & Johnson$158
  • AbbVie$90
  • Pfizer$65
  • Dendreon Pharmaceuticals LLC$32
  • Neotract Inc.$29
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$621100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc9$158
Johnson & Johnson6$158
AbbVie(2 entities)5$90
Pfizer4$65
Dendreon Pharmaceuticals LLC1$32
Neotract Inc.2$29
Antares Pharma, Inc.1$21
180 Medical, Inc.1$20
Rochester Medical Corporation1$16
Axonics, Inc.1$16
Tolmar Pharmaceuticals, Inc.1$16

How this compares

$621 in reported general payments places this provider in the 20th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$94,357
Medicare patients
305
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron98$69,114
Tamsulosin Hcl224$3,256
RenacidinCitric Ac/Gluconolact/Mag Carb16$2,855
Finasteride140$2,611
Testosterone12$1,960
Methenamine Hippurate14$1,198
Trospium Chloride22$1,058
Estradiol16$1,002
Trimethoprim29$985
Fluconazole17$699
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$687
Silodosin11$668
Testosterone Cypionate12$585
NitrofurantoinNitrofurantoin Macrocrystal20$443
Gentamicin Sulfate20$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$158$69,11498 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 300 urology providers in Virginia.

Other urology in Lexington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →